Evidence map›Paper›PMID 28012835›Full record

Trial reportJournal of diabetes and its complications2017

Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan.

Maja Boncelj Svetek, Barbara Eržen, Karin Kanc, Mišo Šabovič

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of diabetes and its complications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03309618. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03309618 nacompleted

Improving Arterial Wall Characteristics in Patients After Myocardial Infarction With a Very Low Dose of Fluvastatin and Valsartan: Proof-of-concept Study

Ran2012Enrolled36Registered outcomes10Posted comparisons0ConditionsMyocardial InfarctionArmslow-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val), Placebo
PMID 22385885PMID 12588755PMID 15452025PMID 20338492PMID 20339920PMID 10913483PMID 10666353PMID 21127698PMID 26214555PMID 28384560other papers from this trial
Open the trial in the graph
NCT03393377 nacompleted

Preventive Arterial Wall Phenotype in Subjects at Moderate Cardiovascular Risk Induced by Very Low-dose Fluvastatin/Valsartan Combination: a Pilot Study

Ran2014Enrolled20Registered outcomes19Posted comparisons0ConditionsAtherosclerosisArmsfluvastatin 10 mg and valsartan 20 mg, Placebo
PMID 27040132PMID 22385885PMID 27222591PMID 28408026PMID 28870631PMID 20338492PMID 24814489PMID 24263076PMID 26567372other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Fluvastatin Sodium Ameliorates Obesity through Brown Fat Activation.International journal of molecular sciences · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Maja Boncelj SvetekDepartment of Vascular Diseases, University Clinical Center Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia.
Barbara ErženDepartment of Vascular Diseases, University Clinical Center Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia.
Karin KancDiabetes & Me, Private Clinic for Diabetes, Židovska 1, 1000 Ljubljana, Slovenia.
Mišo ŠabovičDepartment of Vascular Diseases, University Clinical Center Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia. Electronic address: misabovic@gmail.com.
Ljubljana University Medical Centre · SIHealth Insurance Institute of Slovenia · SI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimPatients with type 2 diabetes are at increased cardiovascular risk. The aim was to explore whether the impaired arterial wall characteristics typical of these patients could be improved by the unique beneficial effects of a very low-dose combination of fluvastatin and valsartan (low-flu/val).

methodsForty middle-aged males (50.4±6.1years) with type 2 diabetes were recruited to a double-blind, randomized study. Patients (N=20) received low-flu/val (10/20mg) or placebo (N=20) over 30days in addition to their regular therapy. Brachial artery flow mediated dilation (FMD), common carotid artery pulse wave velocity (PWV) and β-stiffness were assessed before and after treatment, and 3 and 6months after treatment discontinuation. The treatment was then repeated.

resultsArterial wall characteristics significantly improved. After 30days of intervention, FMD increased from 2.4±0.3 to 4.2±0.3 (p<0.001), PWV decreased from 6.4±0.1 to 5.8±0.2 (p<0.001) and β stiffness decreased from 7.8±0.4 to 6.7±0.4 (p<0.001). Lipids and arterial pressure did not change. After treatment discontinuation, the beneficial effects decreased over the following months. The repetition of treatment completely regained the initial benefits. No changes were observed in the placebo group.

conclusionsLow-flu/val added on-top of optimal therapy substantially improves arterial wall characteristics in patients with type 2 diabetes.

Indexed as

Angiotensin II Type 1 Receptor BlockersArteriesCombined Modality TherapyDiabetes Mellitus, Type 2Diabetic AngiopathiesDouble-Blind MethodDrug MonitoringDrug Therapy, CombinationEndothelium, VascularFatty Acids, MonounsaturatedFluvastatinFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesMaleAngiotensin II Type 1 Receptor BlockersFatty Acids, MonounsaturatedFluvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesValsartanArterial wall characteristicsCardiovascular diseaseClinical trialLow-flu/valType 2 diabetes

Identifiers

PMID28012835
OpenAlexW2567153336

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.